Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 July 2007Website:
http://www.arbutusbio.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 23:04:26 GMTDividend
Analysts recommendations
Institutional Ownership
ABUS Latest News
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment
VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- Mr. Peter Bull and Arbutus Distributors Ltd. (“Arbutus”), a private investment and holding company controlled by Mr. Bull, announced today that Mr. Bull and Arbutus disposed of an aggregate of 2,050,000 common shares (the “Subject Shares”) of ADENTRA Inc. (“ADENTRA”) at a sale price of $38.06 per Subject Share for aggregate gross proceeds of $78,023,000 on the Toronto Stock Exchange through a block sale on May 31, 2024 (the “Transaction”). ADENTRA is incorporated under the federal laws of Canada and has its head office at #B340 20161 86th Avenue, Langley, British Columbia, V2Y 2C1.
WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that two abstracts have been accepted for poster and oral presentations at the European Association for the Study of the Liver (EASL) Congress 2024 taking place June 5 - 8, 2024 in Milan, Italy.
Whitefort Capital Management, LP, a major shareholder of Arbutus Biopharma Corp., has released an open letter to shareholders discussing strategies to enhance value.
Arbutus Biopharma (ABUS) reported a quarterly loss of $0.10 per share, matching the Zacks Consensus Estimate, compared to a loss of $0.10 per share in the same quarter last year.
This is how Arbutus Biopharma (ABUS) and Entera Bio Ltd. (ENTX) have fared in comparison to their industry year-to-date.
Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines.
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL:
Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript
- 1(current)
What type of business is Arbutus Biopharma?
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
What sector is Arbutus Biopharma in?
Arbutus Biopharma is in the Healthcare sector
What industry is Arbutus Biopharma in?
Arbutus Biopharma is in the Biotechnology industry
What country is Arbutus Biopharma from?
Arbutus Biopharma is headquartered in United States
When did Arbutus Biopharma go public?
Arbutus Biopharma initial public offering (IPO) was on 26 July 2007
What is Arbutus Biopharma website?
https://www.arbutusbio.com
Is Arbutus Biopharma in the S&P 500?
No, Arbutus Biopharma is not included in the S&P 500 index
Is Arbutus Biopharma in the NASDAQ 100?
No, Arbutus Biopharma is not included in the NASDAQ 100 index
Is Arbutus Biopharma in the Dow Jones?
No, Arbutus Biopharma is not included in the Dow Jones index
When does Arbutus Biopharma report earnings?
The next expected earnings date for Arbutus Biopharma is 02 August 2024